Samar H. Ibrahim, Binita M. Kamath, Kathleen M. Loomes, Saul J. Karpen – 28 February 2022 – With the application of modern investigative technologies, cholestatic liver diseases of genetic etiology are increasingly identified as the root cause of previously designated “idiopathic” adult and pediatric liver diseases. Here, we review advances in the field enhanced by a deeper understanding of the phenotypes associated with specific gene defects that lead to cholestatic liver diseases.

Christopher A. Dietz, Markus Cornberg – 28 February 2022

Fasiha Kanwal, Saira Khaderi, Amit G. Singal, Jorge A. Marrero, Nicole Loo, Sumeet K. Asrani, Christopher I. Amos, Aaron P. Thrift, Xiangjun Gu, Michelle Luster, Abeer Al‐Sarraj, Jing Ning, Hashem B. El‐Serag – 28 February 2022

Ajay Kumar Patwa, Sumit Rungta, Vivek Kumar – 27 February 2022

Lydia Sastre, Raquel García, Clara Viñals, Antonio J. Amor, Gema Yago, Alicia Hervás, Lorena Sánchez, Joan Trabal, Judit Molero, Laia Escudé, Giulia Pagano, Miquel Blasco, Rosa Gilabert, Pablo Ruiz, Jordi Colmenero, Miquel Navasa, Emilio Ortega, Gonzalo Crespo – 27 February 2022 – Although liver transplantation (LT) recipients are at high cardiovascular risk (CVR), the management of CVR factors (CVRF) after LT is far from optimal and needs to be improved.

Dhiraj Tripathi – 27 February 2022

Antonella Putignano, Thierry Gustot – 27 February 2022

Jordyn Silverstein, Francis Y. Yao, Joshua D. Grab, Hillary J. Braun, John Roberts, Jennifer L. Dodge, Neil Mehta – 27 February 2022 – Living donor liver transplantation (LDLT) is an attractive option to decrease waitlist dropout, particularly for patients with hepatocellular carcinoma (HCC) who face lengthening waiting times. Using the United Network for Organ Sharing (UNOS) national database, trends in LDLT utilization for patients with HCC were evaluated, and post‐LT outcomes for LDLT versus deceased donor liver transplantation (DDLT) were compared.

Meng‐Ju Wu, Lei Shi, Joshua Merritt, Andrew X. Zhu, Nabeel Bardeesy – 27 February 2022 – Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are the most frequently mutated metabolic genes across human cancers. These hotspot gain‐of‐function mutations cause the IDH enzyme to aberrantly generate high levels of the oncometabolite, R‐2‐hydroxyglutarate, which competitively inhibits enzymes that regulate epigenetics, DNA repair, metabolism, and other processes. Among epithelial malignancies, IDH mutations are particularly common in intrahepatic cholangiocarcinoma (iCCA).

Maria Stepanova, Khaled Kabbara, Denise Mohess, Manisha Verma, Alva Roche‐Green, Saleh AlQahtani, Janus Ong, Patrizia Burra, Zobair M. Younossi – 27 February 2022 – As the US population ages, more elderly patients may need liver transplantation. Our aim was to assess recent trends among elderly individuals requiring liver transplant in the United States. Scientific Registry of Transplant Recipients data (2002–2020) were used to select elderly (≥65 years) liver transplant candidates and assess on‐list and posttransplant outcomes.